Company profile: Turn Therapeutics
1.1 - Company Overview
Company description
- Provider of pharmaceutical solutions to reduce the human and economic costs of infection and skin disease, including PermaFusion petrolatum-based liquid-in-oil suspension technology for high-bioavailability delivery; Hexagen FDA-cleared antimicrobial wound dressing; a pre-operative nasal decolonization program targeting MRSA; and onychomycosis treatment.
Products and services
- Hexagen Antimicrobial Wound Dressing: FDA-cleared wound care product employing PermaFusion technology to deliver antimicrobial activity via a petrolatum-based matrix optimized for high bioavailability at minimal active concentrations
- Nasal Decolonization Program: Pre-operative protocol targeting MRSA and other pathogens, utilizing a non-irritating, non-sensitizing formula to reduce surgical site infections and support safer surgical outcomes
- PermaFusion Technology: Petrolatum-based, liquid-in-oil suspension system engineered to deliver active ingredients with high bioavailability at minimal concentrations, enabling efficient drug delivery within advanced wound care applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Turn Therapeutics
Spectral Medical
HQ: Canada
Website
- Description: Provider of therapies and diagnostics for septic shock and sepsis risk, including Toraymyxin (PMX) hemoperfusion to remove endotoxin and the Endotoxin Activity Assay (EAA). Conducts the Tigris Phase 3 study of PMX with standard care. Also offers the DIMI hemodialysis system for continuous renal replacement therapy, licensed for hospitals, clinics, and homes in Canada and the USA, and the SAMI device for continuous renal replacement therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spectral Medical company profile →
Enochian Biopharma
HQ: United States
Website
- Description: Provider of biotechnology, operating as a biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enochian Biopharma company profile →
Armata Pharmaceuticals
HQ: United States
Website
- Description: Provider of bacteriophage-based therapeutics, including AP-PA02 for Pseudomonas aeruginosa respiratory infections, AP-SA02 for drug-resistant Staphylococcus aureus (MRSA/VRSA), and AP-PA03 for P. aeruginosa pneumonia, plus a proprietary synthetic phage engineering platform, phage discovery and phenotyping, and bioinformatics-enabled phage analyses to enhance efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Armata Pharmaceuticals company profile →
GlycoVaxyn
HQ: Switzerland
Website
- Description: Provider of biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology, developing and manufacturing immunogenic glycoprotein conjugate vaccines for a range of bacterial diseases, including pneumococcal and nosocomial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GlycoVaxyn company profile →
Enanta Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule anti-infective drug R&D, discovering and developing therapies including MAVYRET (glecaprevir/pibrentasvir), a hepatitis C virus protease inhibitor regimen requiring only eight weeks of treatment; EDP-514, a novel hepatitis B core inhibitor; zelicapavir (EDP-938), an RSV N-protein inhibitor in Phase 2 for pediatric and adult patients; EDP-323, an RSV L-protein inhibitor; and EDP-235, a 3CL protease inhibitor for COVID-19.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enanta Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Turn Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Turn Therapeutics
2.2 - Growth funds investing in similar companies to Turn Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Turn Therapeutics
4.2 - Public trading comparable groups for Turn Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →